Novo Nordisk A/S Increases Stake in Innate Pharma SA to 9.65%

Novo Nordisk A/S, a Danish company, has filed an amendment to its Schedule 13G, disclosing an increased ownership of 9.65% in Innate Pharma SA. This represents 8,895,649 ordinary shares, including those represented by American Depositary Shares. The filing indicates that Novo Nordisk has sole voting and dispositive power over these shares. The amendment was signed by Karsten Munk Knudsen, Chief Financial Officer of Novo Nordisk, and was filed on October 21, 2025. The event date requiring this filing is July 14, 2025. This filing is an amendment to a previous filing with accession number 0000950103-20-001698.